CAR-T Cell Therapy for ALL

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Relapsed Acute Lymphoblastic Leukemia (ALL)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

National University of Medical Sciences, Clinical Trial Unit, Rawalpindi, Pakistan
Contact: Study coordinator (Maryam Khan, MBBS,MRCP,FCPS(Cl Haem) · maryam.khan9882@gmail.com · +923366395758
Contact: Study coordinator (Nadia Sial, PhD) · nadiaharif@gail.com · +923315582265

Study leads

Maryam Khan, MBBS, MRCP (UK), FCPS(Cl Haem)
Study Chair
National University of Medical Sciences
Tariq Ghafoor
Principal Investigator
National University of Medical Sciences

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Hematologic Malignancy · Large B-cell Lymphoma · Acute Lymphoblastic Leukemia

Abroad (travel likely)RecruitingPHASE1

Los Angeles, United States

Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia

Leukemia

Abroad (travel likely)RecruitingEARLY_PHASE1

Beijing, China

ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.

Lymphoblastic Leukemia, Acute, Childhood · Lymphoblastic Leukemia · Lymphoblastic Leukemia, Acute Adult

Abroad (travel likely)RecruitingPHASE1

Singapore, Singapore

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Acute Lymphoblastic Leukemia · Non-hodgkin Lymphoma

Abroad (travel likely)RecruitingEARLY_PHASE1

Hangzhou, China